Corbus Pharmaceuticals (NASDAQ:CRBP) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05), MarketWatch Earnings reports. The firm had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.66 million.

Shares of NASDAQ CRBP traded down $0.26 during mid-day trading on Friday, reaching $6.61. 942,460 shares of the company were exchanged, compared to its average volume of 1,131,068. The stock has a market capitalization of $435.91 million, a P/E ratio of -10.17 and a beta of 2.16. Corbus Pharmaceuticals has a 1 year low of $4.50 and a 1 year high of $9.95.

Several hedge funds and other institutional investors have recently modified their holdings of CRBP. Fox Run Management L.L.C. purchased a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter worth $144,000. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Corbus Pharmaceuticals by 52.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 35,884 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 12,380 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Corbus Pharmaceuticals by 2,742.5% during the 1st quarter. Royal Bank of Canada now owns 51,961 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 50,133 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Corbus Pharmaceuticals during the 3rd quarter worth $321,000. Finally, Alliancebernstein L.P. lifted its stake in shares of Corbus Pharmaceuticals by 61.5% during the 3rd quarter. Alliancebernstein L.P. now owns 55,400 shares of the biopharmaceutical company’s stock worth $418,000 after purchasing an additional 21,100 shares during the last quarter. Hedge funds and other institutional investors own 42.69% of the company’s stock.

A number of research firms have recently issued reports on CRBP. ValuEngine raised Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 1st. B. Riley began coverage on Corbus Pharmaceuticals in a research report on Wednesday, October 24th. They set a “buy” rating and a $22.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $36.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, October 22nd. Finally, BidaskClub downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $27.33.

COPYRIGHT VIOLATION NOTICE: “Corbus Pharmaceuticals (CRBP) Posts Earnings Results, Misses Estimates By $0.05 EPS” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/10/corbus-pharmaceuticals-crbp-posts-earnings-results-misses-estimates-by-0-05-eps.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

Featured Story: What does EPS mean?

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.